Adaptive Biotechnologies Corp
ADPT
Market Cap$1.45B
Close$
$3.64
61.9% downside
Current Fair Value
61.9% downsideOvervalued by 61.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.45 Billion |
|---|---|
| Enterprise Value | $1.45 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-1.08 |
| Beta | 1.76 |
| Outstanding Shares | 149,195,028 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -10.01 |
|---|---|
| PEG | 26.95 |
| Price to Sales | 9.55 |
| Price to Book Ratio | 9.55 |
| Enterprise Value to Revenue | 7.65 |
| Enterprise Value to EBIT | -10.11 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.29 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Adaptive Biotechnologies Corp
CEO: Chad Robins Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the adap...